GeneDx (NASDAQ:WGS) Issues Quarterly Earnings Results, Misses Estimates By $0.22 EPS

Key Points

• Q results missed: GeneDx reported EPS of ($0.28), missing estimates by $0.22, and revenue of $102.25M versus $112.46M expected, leaving a negative net margin of 4.92% despite a positive ROE of 14.73%.
• Shares rose about 3.9% to $67.93 on heavy volume after the release, though the stock remains well below its one‑year high ($170.87) with a market cap of $1.99B.
• Insider selling and analyst moves: Insiders sold roughly 109,989 shares (~$7.89M) in the last 90 days (including CEO/CFO sales to cover tax withholding), while analysts have trimmed targets yet the consensus is a Moderate Buy with an average price target of $134.17.

GeneDx (NASDAQ:WGS - Get Free Report) posted its earnings results on Monday. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.22), FiscalAI reports. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The business had revenue of $102.25 million for the quarter, compared to analysts' expectations of $112.46 million.

GeneDx Trading Up 3.9%

Shares of NASDAQ WGS traded up $2.55 during midday trading on Monday, reaching $67.93. The company had a trading volume of 1,267,107 shares, compared to its average volume of 732,351. GeneDx has a one year low of $55.17 and a one year high of $170.87. The company has a quick ratio of 2.34, a current ratio of 2.46 and a debt-to-equity ratio of 0.16. The firm's fifty day moving average price is $71.45 and its 200-day moving average price is $107.17. The stock has a market cap of $1.99 billion, a PE ratio of -90.57 and a beta of 2.06.

Insider Buying and Selling

In other news, CEO Katherine Stueland sold 2,172 shares of the business's stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total value of $141,592.68. Following the completion of the sale, the chief executive officer owned 93,216 shares of the company's stock, valued at approximately $6,076,751.04. The trade was a 2.28% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Kevin Feeley sold 392 shares of the company's stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $65.19, for a total value of $25,554.48. Following the transaction, the chief financial officer directly owned 34,942 shares of the company's stock, valued at $2,277,868.98. The trade was a 1.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 109,989 shares of company stock worth $7,888,023. Insiders own 29.60% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Cerity Partners LLC raised its position in GeneDx by 6.0% during the 4th quarter. Cerity Partners LLC now owns 2,527 shares of the company's stock valued at $329,000 after purchasing an additional 142 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in GeneDx by 5.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company's stock valued at $399,000 after purchasing an additional 181 shares during the last quarter. Kestra Advisory Services LLC bought a new position in GeneDx during the 4th quarter valued at approximately $27,000. Quarry LP raised its position in GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company's stock valued at $32,000 after purchasing an additional 209 shares during the last quarter. Finally, Greenline Wealth Management LLC bought a new position in GeneDx during the 4th quarter valued at approximately $33,000. Institutional investors own 61.72% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Guggenheim cut their price objective on GeneDx from $170.00 to $100.00 and set a "buy" rating for the company in a report on Monday, March 30th. Canaccord Genuity Group set a $100.00 price objective on GeneDx and gave the stock a "buy" rating in a report on Monday, April 20th. Wall Street Zen cut GeneDx from a "buy" rating to a "hold" rating in a report on Sunday, February 8th. Jefferies Financial Group set a $150.00 price objective on GeneDx in a report on Monday, February 23rd. Finally, Piper Sandler reiterated an "overweight" rating and issued a $130.00 price objective (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, GeneDx currently has a consensus rating of "Moderate Buy" and an average price target of $134.17.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.